Home cardiovascular
 

Keywords :   


Tag: cardiovascular

05.23.12 -- Study Reveals Biological Link Between Air Pollution, Cardiovascular Disease

2016-06-13 17:37:22| pollutiononline Home Page

05/23/12 Pollution Online Newsletter

Tags: link air study disease

 

Can alcohol reduce the risk of cardiovascular disease? - International Scientific Forum on Alcohol Research Critique 177

2015-12-21 14:47:00| Daily beverage news and comment - from just-drinks.com

While there have been many observational studies of the relation of alcohol consumption to health risks and benefits, the number of clinical trials of alcohol administration for its health effects are limited.

Tags: forum international research risk

 
 

Philips Introduces IntelliSpace Cardiovascular at ESC Congress 2015

2015-09-04 12:31:13| Industrial Newsroom - All News for Today

ANDOVER, Massachusetts and LONDON - Connected cardiology solution provides holistic view of patient care across the entire cardiovascular journey Royal Philips [http://www.usa.philips.com (NYSE: PHG, AEX: PHIA) today announced the European debut of IntelliSpace Cardiovascular...

Tags: philips congress introduces cardiovascular

 

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Will Be Presented at the European Society of Cardiology Congress

2015-08-20 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA (sitagliptin), and real-world data from the Dyslipidemia International Study (DYSIS I and DYSIS II) will be presented at the upcoming European Socie Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the of will study

 

AstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs For Cardiovascular, Metabolic And Renal Diseases

2015-08-04 03:27:28| drugdiscoveryonline News Articles

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

Tags: develop discover drugs diseases

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »